U.S. patent application number 14/854390 was filed with the patent office on 2016-04-28 for scleral translocation elasto-modulation methods and apparatus.
The applicant listed for this patent is ALEYEGN, INC.. Invention is credited to Rajeev HEREKAR, Satish HEREKAR.
Application Number | 20160113816 14/854390 |
Document ID | / |
Family ID | 51581613 |
Filed Date | 2016-04-28 |
United States Patent
Application |
20160113816 |
Kind Code |
A1 |
HEREKAR; Satish ; et
al. |
April 28, 2016 |
SCLERAL TRANSLOCATION ELASTO-MODULATION METHODS AND APPARATUS
Abstract
A laser delivery system is configured to delivery light energy
to soften and realign the tissue of the eye in order to increase
accommodation and treat glaucoma. The laser system can be
configured to increase a circumlental space of the eye and increase
movement of a posterior vitreous zonule in order to increase
accommodation. The light energy may comprise wavelengths strongly
absorbed by collagen of the sclera. In many embodiments a heat sink
is provided to couple to the conjunctiva and the heat sink
comprises a material transmissive to the light energy absorbed by
collagen, for example Zinc Selenide. The heat sink can be chilled
to inhibit damage to the conjunctiva of the eye. In many
embodiments, one or more layers of the epithelium of the eye remain
substantially intact above the zone where the eye has been treated
when the heat sink has been removed.
Inventors: |
HEREKAR; Satish; (Palo Alto,
CA) ; HEREKAR; Rajeev; (San Diego, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ALEYEGN, INC. |
Menlo Park |
CA |
US |
|
|
Family ID: |
51581613 |
Appl. No.: |
14/854390 |
Filed: |
September 15, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/US14/23763 |
Mar 11, 2014 |
|
|
|
14854390 |
|
|
|
|
61801041 |
Mar 15, 2013 |
|
|
|
61886478 |
Oct 3, 2013 |
|
|
|
61936054 |
Feb 5, 2014 |
|
|
|
Current U.S.
Class: |
606/4 |
Current CPC
Class: |
A61F 2009/00895
20130101; A61F 9/008 20130101; A61F 2009/00865 20130101; A61F
2009/00868 20130101; A61F 2009/00887 20130101; A61F 9/00821
20130101 |
International
Class: |
A61F 9/008 20060101
A61F009/008 |
Claims
1. An apparatus to treat an eye, the apparatus comprising: a source
of energy to soften a sclera of the eye; a processor comprising
instructions to treat the eye with the source of energy in order to
soften the sclera between a lens equator and an insertion of
posterior zonule into an ora serrata of the eye.
2. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye with the energy source to increase a
circumlental space of the eye.
3. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye with the energy source to increase
movement of a posterior vitreous zonule when the eye
accommodates.
4. An apparatus as in claim 1, further comprising: a cooling
structure to contact an outer surface of the eye, wherein the
processor comprises instructions to treat the eye with the source
of energy when the cooling structure contacts the outer surface of
the eye.
5. An apparatus as in claim 4, wherein the cooling structure
comprises one or more of a heat sink or a chiller.
6. An apparatus as in claim 5, wherein the cooling structure
comprises the heat sink coupled to the chiller, the heat sink
comprising a surface to contact the eye and conduct heat from the
eye, the chiller comprising a substance having a temperature less
than about 20 degrees Celsius and greater than a freezing
temperature of saline, wherein the substance comprises a fluid and
a fluidic channel extends from the heat sink to the chiller to
cycle the fluid through the heat sink and the chiller.
7. An apparatus as in claim 4, wherein the cooling structure is
shaped to contact a conjunctiva of the eye.
8. An apparatus as in claim 4, wherein the cooling structure
comprises a material transmissive to energy of the source.
9. An apparatus as in claim 4, wherein the energy source comprises
a laser beam and the cooling structure comprises a material
transmissive to the laser beam.
10. An apparatus as in claim 4, wherein the energy source comprises
a laser beam and the cooling structure comprises a material
transmissive to the laser beam and wherein the material comprises
ZnSe and the laser beam comprises a wavelength within a range from
about 5.8 to about 6.6 um.
11. An apparatus as in claim 10, wherein the laser beam is
configured to have a greater absorbance by stroma than by
water.
12. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that vitreous zonules at the ora
serrata move at least anteriorly when the eye accommodates at least
about one diopter.
13. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that the vitreous zonules at the
ora serrata move at least anteriorly at least about 1 mm when the
eye accommodates the at least about one diopter and wherein the
softened scleral tissue moves interiorly toward an optical axis of
the eye.
14. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that an apex of a ciliary body
is translocated away from an optical axis of the eye to increase a
circumlental space of the eye.
15. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that energy is transmitted
through a conjunctiva of the eye to soften the sclera.
16. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that a conjunctiva of the eye
comprises at least one layer of viable cells under a location of
the conjunctiva irradiated with an energy source and a heated
region comprising softened scleral tissue.
17. A method as in claim 16, wherein the processor comprises
instructions to treat the eye such that a conjunctiva of the eye
comprises at least one layer of viable cells under a location of
the conjunctiva irradiated with an energy source and a heated
region comprising softened scleral tissue.
18. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that a conjunctiva of the eye is
cooled with one or more of a heat sink or a chiller and wherein the
conjunctiva of the eye comprises a peak temperature less than a
peak temperature of the sclera.
19. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that a conjunctiva of the eye is
cooled with one or more of a heat sink or a chiller and wherein the
conjunctiva of the eye is heated less than the sclera.
20. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that at least about half of an
electromagnetic light energy is absorbed with the conjunctiva of
the eye and wherein a scleral stroma of the eye is heated more than
the conjunctiva of the eye.
21. A apparatus as in claim 19, wherein the processor comprises
instructions to treat the eye such that an outer epithelial layer
of the conjunctiva is heated to a temperature of no more than about
43 degrees Celsius and a portion of the scleral stroma is heated to
at least about 50 degrees Celsius to soften the scleral stroma.
22. An apparatus as in claim 1, wherein the processor comprises
instructions to treat the eye such that a conjunctiva of the eye is
incised in order to treat the sclera.
23-68. (canceled)
Description
CROSS-REFERENCE
[0001] The present application is a continuation of
PCT/US14/023763, filed on Mar. 11, 2014, entitled "SCLERAL
TRANSLOCATION ELASTO-MODULATION METHODS AND APPARATUS" [attorney
docket no. 48848-703.601], which claims priority to U.S. App. Ser.
No. 61/801,041, filed on Mar. 15, 2013, entitled "TREATMENT METHODS
AND SYSTEMS FOR PRESBYOPIA AND GLAUCOMA" [attorney docket no.
48848-703.101]; U.S. App. Ser. No. 61/886,478, filed on Oct. 3,
2013, entitled "SCLERAL TRANSLOCATION ELASTO-MODULATION METHODS AND
APPARATUS" [attorney docket no. 48848-703.102]; U.S. App. Ser. No.
61/936,054, filed on Feb. 5, 2014, entitled "SCLERAL TRANSLOCATION
ELASTO-MODULATION METHODS AND APPARATUS" [attorney docket no.
48848-703.103]; the entire disclosures of which are incorporated
herein by reference.
BACKGROUND
[0002] The field of the present invention is related generally to
medical devices and methods, and more particularly relates to
methods and apparatus for treating the eye.
[0003] Existing methods and apparatus for treating presbyopia and
glaucoma can produce less than ideal results. For example,
multifocal lenses can degrade vision with at least some blur at
near vision and far vision. Prior attempts at restoring natural
movement of the lens have resulted in less than ideal results in at
least some instances. Although accommodating intraocular lenses
(hereinafter "IOLs") have been used, these accommodating lenses can
provide less than ideal amounts of accommodation in at least some
instances. Also, prior methods and apparatus for treating glaucoma
can be less than ideal in at least some instances.
[0004] In light of the above, it would be beneficial to provide
improved methods and apparatus for treating presbyopia and
glaucoma. Ideally, such methods and apparatus would restore
accommodation in the natural lens of the eye and provide improved
accommodation with accommodating IOLs.
SUMMARY
[0005] Embodiments of the present invention provide improved
methods and apparatus for treatment of the eye. The methods and
apparatus as disclosed herein provide improved treatments of one or
more of presbyopia or glaucoma, and in many embodiments both.
Although many embodiments are described with reference to a natural
lens of the eye, the embodiments disclosed herein can be used to
improve accommodation with accommodating IOLs.
[0006] In many embodiments, the eye is treated such that the
posterior vitreous zonules can move at least anteriorly to allow
the lens capsule to move anteriorly or reshape, or both, in order
to provide improved accommodation. In many embodiments, the eye is
treated in order to provide improved anterior-centripetal movement
of the ciliary body at the insertion of the posterior vitreous
zonule into the ciliary body. Alternatively or in combination, the
eye can be treated so as to increase the circumlental space between
the ciliary body and lens capsule in order to provide increased
amounts of accommodation. The increased amount of anterior movement
of the posterior vitreous zonule from the unaccommodated state to
the accommodative state can be within a range from about 250 to
about 1000 um, for example.
[0007] The sclera can be softened posterior to the lens equator and
anterior to the insertion location of the posterior zonules near
the ora serrata in one or more of many ways in order to encourage
movement of the posterior vitreous zonules at least anteriorly in
order to provide improved accommodation, such as with one or more
of light energy, ultrasound energy, electrical energy, heating,
electroporation, optoporation, or photonic desincrustation or
galvanic desincrustation. In many embodiments, the softening of the
scleral tissue posterior to the lens equator provides at least
about one millimeter of anterior movement of the posterior vitreous
zonules lens and/or capsule so as to provide at least about one
diopter of accommodation. In many embodiments, the movement of the
posterior vitreous zonules near the insertion into the ora serrata
allows the lens to move anteriorly and to reshape itself with a
more convex curvature. In many embodiments, the sclera is softened
without removal of collagen from the tissue, which can inhibit
regression of the softening effect. The softening of the sclera can
be performed so as to inhibit damage to the ciliary body and
choroid, and the energy such as light energy can be directed in a
manner that avoids the ciliary body and choroid. The scleral
softening can be performed such that the zonules of the eye
comprise slack subsequent to treatment in order to inhibit changes
in the position of the lens and/or capsule when the eye is
configured for far vision and inhibit changes to the far vision
refraction of the eye. In many embodiments, the posterior vitreous
zonules comprise at least some slack in order to allow the lens
capsule to move anteriorly. In many embodiments, the softened
scleral tissue between the lens equator and insertion of the
posterior vitreous zonules at the ora serrata moves interiorly
toward an optical axis of the eye when the eye accommodates, and
may provide inward movement of the posterior vitreous zonules. In
many embodiments, the scleral tissue is translocated near the
ciliary body apex in order to increase the circumlental space. The
translocation of the scleral tissue and ciliary body apex can be
performed without tissue removal, in order to decrease regression
of an initial effect and in order to decrease the invasiveness of
the procedure.
[0008] In many embodiments, light energy is used to soften the
tissue, and the light energy comprises wavelengths that are
strongly absorbed by the collagen of the sclera or the water of the
sclera, or both for example. In many embodiments, the light energy
comprises wavelengths that are absorbed more strongly by stromal
tissue than water, for example light comprising a wavelength within
a range from about 4 to 6 um, such as from about 5.5 to 6.6 um. The
light energy absorbed more strongly by stroma than water has the
advantage of providing more accurate treatment with less
interference with water, and can allow the tissues of the eye to
retain healthy amounts of water during treatment, for example
tissues of the conjunctiva of the eye. Also, interference from
water based surgical fluids such as saline and anesthetics can be
substantially inhibited.
[0009] In many embodiments a heat sink is provided to couple to the
conjunctiva and the heat sink comprises a material transmissive to
the light energy, such as sapphire or Zinc Selenide (hereinafter
"ZnSe"). The heat sink material can be configured to transmit light
energy absorbed more strongly by the stroma than water, and may
comprise Zinc Selenide (hereinafter "ZnSe"), for example. The heat
sink can be chilled to inhibit damage to the conjunctiva of the
eye. The heat sink can provide improved transmission of light
energy when condensation is present, as the condensed water may be
less strongly absorbed by the laser beam. In many embodiments, one
or more layers of the epithelium of the eye (basal layer, wing
layer or squamous layer) remains substantially intact above the
zone where the eye has been treated, for example at least one layer
of viable epithelial cells can remain intact when the heat sink is
removed.
[0010] In many embodiments, the optically transmissive material of
the heat sink is shaped and optically configured with smooth
surfaces so as to comprises an optically transparent heat sink such
as a lens. The heat sink may comprise a window of the optically
transmissive material, and can be one or more of many shapes such
as a flat on opposing surfaces, plano-concave, or convex-concave.
The convex-concave heat sink window may comprise a meniscus shaped
lens, having substantial optical power or no substantial optical
power, for example.
[0011] The location of the heat sink can be fixed in relation to a
fixed structure of the laser system in order to fix the location of
the eye, and the heat sink may comprise one or more curved surfaces
such as a concave surface to engage the eye. In many embodiments,
an arm extends from the fixed structure of the laser system to the
heat sink in order to fix the location of the heat sink.
[0012] The laser may comprise one or more of many lasers emitting
one or more of many wavelengths, such as infrared lasers. In many
embodiments, the laser comprises a quantum cascade laser configured
to emit light having a wavelength within a range from about 5.8 to
about 6.6 um, for example from about 6 to about 6.25 um. Such
lasers are commercially available, and con be configured by a
person of or
[0013] In many embodiments the treatment apparatus comprises an
energy source such as a laser and a docking station to retain the
eye. In many embodiments the docking station comprises a chilled
optically transmissive heat sink to couple to the eye. The docking
station couples to the eye such that the heat sink contacts the
conjunctiva of the eye and fixes the working distance of the eye
from the surgical laser, such that the scleral treatment comprising
softening posterior to the lens equator can be performed
accurately. In many embodiments, heat sink is chilled such that at
least one epithelial layer of the conjunctiva of the eye above the
treated tissue remains viable, in order to expedite healing of the
eye and decrease invasiveness of the procedure. The chilled heat
sink structure can be chilled to a temperature within a range from
above the freezing temperature of the eye and saline, at about -3
degrees Celsius (C), to below an ambient room temperature of about
20 degrees Celsius. Alternatively, a heat sink can be provided
without chilling. In many embodiments, the freezing temperature of
the eye corresponds to the freezing temperature of saline, about -3
degrees, for example. In many embodiments, the apparatus comprises
a scanner to scan the laser beam. The laser beam can be pulsed or
continuous, and in many embodiments comprises a continuous laser
beam configured to inhibit temperature spikes related to ablation
of the eye. In many embodiments the laser irradiance comprises a
temporal and spatial profile to inhibit transient heating peaks of
the tissue that can be related to removal of tissue such as
ablation. The scanner can be configured to scan the laser beam in a
plurality of quadrants, such as for quadrants with untreated
regions between each of the quadrants to inhibit damage to muscles
of the eye located between the treatment quadrants.
[0014] While reference is made to softening tissue with light
energy, other forms of energy can be used to soften tissue such as
one or more of electroporation, microwave, thermal, electrical
energy or di-electrophoretic energy and combinations thereof. In
many embodiments, electroporation needles can be provided with a
shaped array having four quadrants sized to extend through the
conjunctiva and deliver electroporation energy beneath the
conjunctiva. Alternatively, shaped contact electrodes can be
provided without needles such that the current is passed through
the epithelial layer of the conjunctiva to targeted regions of the
sclera in order to soften at least a portion of the scleral tissue
between the lens equator and insertion location of the posterior
vitreous zonules. The electroporation to soften the sclera
comprises an oscillating electric field to pass current in an
electroporation treatment profile similar to the optical treatment
profile disclosed herein.
[0015] The embodiments disclosed herein provide improved
accommodation of the eye with an increase of one or more of the
perilenticular space or a softened and/or plasticized portion of
scleral or corneal tissue. The perilenticular space extending
between the ciliary body and the lens of the eye can be increased
with tissue stabilization and shrinking. In some embodiments, the
perilenticular space is increased with cross-linking of an outer
portion of a sclera of the eye near a ciliary body of the eye so as
to stabilize the outer portion of scleral tissue with increased
stiffness, and an inner shrinking treatment of an inner portion of
the sclera located inwardly from the outer portion and toward the
lens of the eye. The shrinking of the inner portion can be combined
with the stabilization of the outer portion such that the inner
surface of the ciliary body is urged away from the lens capsule so
as to increase the perilenticular space. The portion of softened
and/or plasticized scleral tissue can be located between sclera
disposed over the ora serrata and sclera corresponding to the
equator of the lens of the eye in order to allow the lens capsule
and lens to move an increased amount in order to restore
accommodation. The softening and/or plasticizing of the scleral
tissue portion can provide improved accommodation with increased
mobility of the posterior vitreous zonules extending between the
ciliary body and the ora serrata. In many embodiments, the
stiffening of the outer portion of the sclera and shrinking of the
inner portion of the sclera provides improved drainage of the
channels of the trabecular meshwork of the eye, and can be related
to increased channel sizes of this tissue structure.
[0016] In many embodiments, tissue stabilization and shrinking can
be used to treat glaucoma. An outer portion of the sclera can be
treated with cross-linking to add stiffness and stabilize the outer
portion. An inner portion disposed inwardly from the outer portion
can be treated with shrinking in order to urge one or more tissue
structures of the eye toward the stabilized portion and increase
channel sizes of the one or more tissue structures of the eye such
as Schlemm's canal and one or more channels of the trabecular
meshwork.
[0017] In an aspect, a method is provided for treating an eye. The
method can include cross-linking an outer portion of the eye and
shrinking an inner portion of the eye, such that a tissue structure
of the eye has moved outwardly toward the cross-linked outer
portion when the inner portion has shrank. Outward can include
radially outward away from an optical axis of the eye.
[0018] In many embodiments, the outer portion can include a sclera
of the eye through which a plane defining an equator of the lens of
the eye extends in order to treat a presbyopia of the eye. The
outer sclera portion can include a cross-linked profile prior to
shrinking. The cross-linked profile can be substantially maintained
when the inner portion shrinks. A cross-sectional thickness of the
sclera can extend from an outer surface of the sclera adjacent a
conjunctiva to an inner surface of the sclera adjacent a trabecular
meshwork through the outer portion and the inner portion. The
cross-sectional thickness of the sclera can decrease from a first
thickness prior to shrinking to a second thickness subsequent to
shrinking, the second thickness less than the first thickness. The
inner surface can include an inner surface profile extending along
an inner side of the sclera. The outer surface can include an outer
surface profile extending along an outer side of the sclera. The
inner surface can deflect outwardly an amount greater than the
outer surface deflects inwardly when the inner portion has
shrunk.
[0019] In many embodiments, the tissue structure of the eye can
include a ciliary body of the eye in order to increase a
perilenticular space of the eye. The tissue structure of the eye
can include one or more of a portion of the cornea or a portion of
the sclera lateral to the Schlemm's canal in order to increase a
cross-sectional size of one or more of the Schlemm's canal or a
trabecular meshwork of the eye in order to treat glaucoma of the
eye. The tissue structure of the eye can include a portion of the
sclera lateral to a trabecular meshwork of the eye in order to
increase a cross-sectional size of channels of the trabecular
meshwork in order to treat glaucoma of the eye.
[0020] In many embodiments, the eye includes a conjunctiva disposed
over a sclera and the inner portion is treated through the
conjunctiva of the eye. The eye can include a conjunctiva and the
conjunctiva can be moved away from the sclera to treat the inner
portion.
[0021] In many embodiments, the outer portion can be cross-linked
with a cross-linking agent including one or more of: riboflavin,
rose bengal, methylene blue, indocyanine green, genipin, threose,
methylglyoxal, glyceraldehydes, aliphatic .beta.-nitro alcohols, or
black currant extract, or an analog of any of the above. The inner
portion can shrink with one or more of thermal energy,
radiofrequency energy, electrical energy, microwave energy, or
light energy. The method can include placing a heat sink over the
outer portion to conduct heat away from the outer portion when the
inner portion is heated. The inner portion can shrink with light
energy and the heat sink can include a material transmissive to
wavelengths of the light energy in order to heat the tissue with
light energy absorbed beneath the heat sink. The inner portion can
be heated to a temperature within a range from about 50 to about 70
degrees Centigrade in order to shrink the tissue. The portion can
be heated within the range without substantially weakening the
tissue. A layer of conjunctiva located above the inner portion can
remain substantially viable when the inner portion is treated in
order to inhibit pain and swelling.
[0022] In many embodiments, the method can include softening a
portion of scleral tissue of the eye, the sclera tissue extending
posterior to an equatorial plane of a lens of the eye and anterior
to an insertion location of posterior vitreous zonules proximate an
ora serrata of the eye. The portion can be heated to a temperature
within a range from about 70 to about 90 degrees Centigrade in
order to weaken the tissue. The softened portion can include four
softened portions, each corresponding to four locations away from
muscles of the eye including inferior muscles, superior muscles,
nasal muscles, and temporal muscles in order to inhibit damage to
the muscles.
[0023] In another aspect, a method for treating an eye is provided.
The method can include softening a portion of sclera tissue of the
eye, the portion of sclera tissue extending posterior to an
equatorial plane of a lens of the eye and anterior to an insertion
location of posterior vitreous zonules proximate an ora serrata of
the eye.
[0024] In another aspect, an apparatus configured to perform the
method of any of the preceding embodiments is provided.
[0025] In another aspect, an apparatus to treat the eye is
provided. The apparatus can include a cross-linking agent to
cross-link an outer portion of a sclera of the eye. The apparatus
can include an energy source to shrink an inner portion of the
sclera of the eye and move a tissue structure outward toward the
outer portion when the inner portion has shrank. The cross-linking
agent can include one or more of a chemical agent or
photosensitizers. The energy source can include one or more of a
light energy source, a thermal energy source, an electrical energy
source, an RF energy source, or a microwave energy source. The
energy source can include a microelectrode array. The cross-linker
can include a chemical photosensitizer.
[0026] In many embodiments, the energy source can include a light
energy source, in which the light energy source configured to emit
at least one wavelength of light to cross-link the outer portion
and shrink the inner portion. The light source can include a single
light source to emit a wavelength of light to cross-link the outer
portion and shrink the inner portion, optionally, to shrink the
inner portion and cross-link the outer portion together, or
optionally, to shrink the inner portion after the outer portion has
been cross-linked, and combinations thereof. The light source can
include a first light source to cross-link the outer portion and a
second light source to shrink the inner portion. The first light
source can be configured to emit a first light energy including a
first wavelength of light and the second light source can be
configured to emit a second light energy including a second
wavelength of light, the first wavelength different from the second
wavelength. The light source can include a softening light source
to soften a tissue of the sclera.
[0027] In another aspect, a method of treating an eye is provided.
An inner portion of the eye is shrunk to cause a tissue structure
of the eye to move outwardly toward an outer portion of the
eye.
[0028] In another aspect, an apparatus configured to perform the
method of any one of the preceding embodiments is provided.
[0029] These and other embodiments are described in further detail
in the following description related to the appended drawings.
INCORPORATION BY REFERENCE
[0030] All publications, patents, and patent applications mentioned
in this specification are herein incorporated by reference to the
same extent as if each individual publication, patent, or patent
application was specifically and individually indicated to be
incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0031] A better understanding of the features and advantages of the
present disclosure will be obtained by reference to the following
detailed description that sets forth illustrative embodiments, in
which the principles of the disclosure are utilized, and the
accompanying drawings of which:
[0032] FIG. 1 illustrates a presbyopic eye in a configuration for
far vision, in accordance with embodiments;
[0033] FIG. 2 illustrates the presbyopic eye of FIG. 1 attempting
to correct for near vision, in accordance with embodiments;
[0034] FIG. 3 illustrates stabilization of an eye by cross-linking
to treat presbyopia, in accordance with embodiments;
[0035] FIG. 4 illustrates a heat sink placed over the eye of FIG. 3
to treat presbyopia, in accordance with embodiments;
[0036] FIG. 5 illustrates a planned treatment zone to expand the
circumlental space in the eye of FIG. 4 to treat presbyopia, in
accordance with embodiments;
[0037] FIG. 6 illustrates laser treatment of the eye of FIG. 5 to
treat presbyopia, in accordance with embodiments;
[0038] FIG. 7 illustrates the eye of FIG. 6 in a configuration for
near vision, in accordance with embodiments;
[0039] FIG. 8 illustrates the eye of FIG. 7 in a configuration for
far vision, in accordance with embodiments;
[0040] FIG. 9 illustrates laser softening of the insertion location
of the posterior vitreal zonules of the eye of FIG. 8 to treat
presbyopia, in accordance with embodiments;
[0041] FIG. 10 illustrates a planned treatment to enhance corneal
bending of the eye of FIG. 9 to treat presbyopia, in accordance
with embodiments;
[0042] FIG. 11 illustrates a heat sink placed on the eye of FIG. 10
to enhance corneal bending to treat presbyopia, in accordance with
embodiments.
[0043] FIG. 12 is a simplified block diagram illustrating steps of
a method to presbyopia, in accordance with embodiments;
[0044] FIG. 13 illustrates a magnetic resonance image (hereinafter
"MRI") of a non-presbyopic eye in a far vision configuration, in
accordance with embodiments;
[0045] FIG. 14 illustrates a MRI of a non-presbyopic eye in a near
vision configuration, in accordance with embodiments;
[0046] FIG. 15 illustrates a video image of laser treatment to
shrink scleral tissue, in accordance with embodiments;
[0047] FIG. 16 illustrates the video image of FIG. 15 at a later
time point during application of laser treatment, in accordance
with embodiments;
[0048] FIG. 17 illustrates the video image of FIG. 16 at a later
time point, in accordance with embodiments;
[0049] FIG. 18 illustrates the video image of FIG. 17 at a later
time point showing involution of the marker vessel and tissue into
the laser treatment spot, in accordance with embodiments;
[0050] FIG. 19 illustrates a plot of uncorrected near visual acuity
(hereinafter "UNVA") versus IOP, in accordance with
embodiments;
[0051] FIG. 20 illustrates a system for treating an eye, in
accordance with embodiments;
[0052] FIGS. 21A and 21B show a mask pattern and a treatment scan
pattern for treating an eye, respectively, in accordance with
embodiments;
[0053] FIG. 22 illustrates an optical coherence tomography
(hereinafter "OCT") image of a subsurface laser treatment of
cornea, in accordance with embodiments;
[0054] FIG. 23A illustrates an OCT image of a cornea of an eye
treated with a hollow microelectrode array, in accordance with
embodiments;
[0055] FIG. 23B illustrates an image of the fluorescein stain
pattern of the eye of FIG. 23A, in accordance with embodiments;
[0056] FIG. 23C illustrates an OCT image of the cornea of FIG. 23A
with increased grey levels, in accordance with embodiments;
[0057] FIG. 23D illustrates a fluorescence image of the eye of FIG.
23A, in accordance with embodiments;
[0058] FIGS. 24A and 24B show a treatment apparatus, in accordance
with embodiments;
[0059] FIG. 25A shows a treatment region of the sclera and
conjunctiva under a heat sink comprising a cooling lens contacting
the conjunctiva;
[0060] FIG. 25B shows a region of the conjunctiva above the scleral
softening treatment region as in 25A comprising an intact
epithelial layer subsequent to delivery of laser energy with the
optically transmissive heat sink contacting the tissue;
[0061] FIG. 26A shows a tissue depth penetration of a laser beam,
in accordance with embodiments;
[0062] FIG. 26B shows a tissue heating profile with scanning of a
laser beam as in FIG. 26A, in accordance with embodiments;
[0063] FIG. 27A shows absorbance spectra, suitable for
incorporation in accordance with embodiments;
[0064] FIG. 27B shows absorbance spectra in accordance with
embodiments.
[0065] FIG. 28 shows a user interface, in accordance with
embodiments; and
[0066] FIG. 29 shows array ultrasound transmitter array to treat
tissue, in accordance with embodiments;
[0067] FIG. 30A shows a presbyopic eye in unaccommodated state in
accordance with embodiments;
[0068] FIG. 30B shows an eye as in FIG. 30A and in an accommodated
state;
[0069] FIG. 30C shows a presbyopic eye suitable for treatment in an
unaccommodated state in accordance with embodiments;
[0070] FIG. 30D shows a presbyopic eye suitable for treatment in an
accommodated state in accordance with embodiment.
DETAILED DESCRIPTION
[0071] A better understanding of the features and advantages of the
present disclosure will be obtained by reference to the following
detailed description that sets forth illustrative embodiments, in
which the principles of embodiments of the present disclosure are
utilized, and the accompanying drawings.
[0072] Although the detailed description contains many specifics,
these should not be construed as limiting the scope of the
disclosure but merely as illustrating different examples and
aspects of the present disclosure. It should be appreciated that
the scope of the disclosure includes other embodiments not
discussed in detail above. Various other modifications, changes and
variations which will be apparent to those skilled in the art may
be made in the arrangement, operation and details of the method and
apparatus of the present disclosure provided herein without
departing from the spirit and scope of the invention as described
herein.
[0073] The embodiments disclosed herein can be combined in one or
more of many ways to provide improved methods and apparatus for
treating the eye.
[0074] As used herein like characters identify like elements.
[0075] As used herein A and/or B encompasses one or more of A or B,
and combinations thereof such as A and B.
[0076] The embodiments as disclosed herein provide improved methods
and apparatus for the treatment of one or more of presbyopia or
glaucoma, in accordance with embodiments. For example, presbyopia
treatments as disclosed herein can have a beneficial effect on a
patient's intraocular pressure (hereinafter "IOP"). Alternatively
or in combination, the treatment can be directed to the treatment
of glaucoma, for example. The treatments and apparatus disclosed
herein can be combined with many known methods and apparatus for
treatment. For example, the restoration of accommodation as
described herein can be combined with one or more of many known
prior accommodating IOLs, for example. Alternatively or in
combination, the methods and apparatus as disclosed herein can be
combined with one or more known glaucoma therapies.
[0077] Provisional Application to U.S. App. Ser. No. 61/801,041,
filed on Mar. 15, 2013, which has been previously incorporated
herein by reference, discloses improved methods and apparatus to
treat presbyopia and/or glaucoma in accordance with many
embodiments disclosed herein. In many embodiments, tissue is not
substantially removed and is moved to a new location with the
treatment. This movement of collagenous tissue from a first
location to a second location provides improved treatment with less
regression of effect and healing. The methods and apparatus
disclosed therein describe treatment of the eye without ablation
and without formation of hard spots as can be formed when a laser
removes tissue with heat. In many embodiments, the treatment can be
performed without incisions of the eye, in order to decrease the
invasiveness of the procedure and decrease regression of
effect.
[0078] In many embodiments, the methods and apparatus disclosed
herein provide scleral translocation and elasto-modulation
(hereinafter "STEM") of an eye in order to at least partially
restore accommodation of the eye and treat presbyopia or
glaucoma.
[0079] In many embodiments, the STEM procedure provides
extra-corneal and/or extra-lenticular laser treatment to soften
and/or plasticize the sclera and/or peripheral cornea. The STEM
procedure can provide non-reductive and non-ablative restoration of
accommodative power compatible with the Helmholtz theory of
accommodation. Treatment can be applied to the eye from the scleral
spur to the ora serrata while avoiding damage to limbal stem cells,
conjunctiva, epithelium, and eye muscles. The STEM procedure can
include elasto-modulation to one or more of: soften and/or
plasticize scleral regions near the ciliary body apex to enhance
inward movement of the ciliary body during accommodation; soften
and/or plasticize scleral regions near the insertions of the
posterior vitreous zonules to enhance anterior movement of the
ciliary body during accommodation; or soften and/or plasticize
regions of the sclera and/or cornea near the sclera spur to enhance
corneal asphericity and/or flexing during accommodation.
[0080] In many embodiments, the STEM procedure provides application
of heat to the eye to produce a thermo-mechanical response in a
tissue of the eye, such as in the cornea and/or sclera. For
example, the cornea and/or sclera can be heated to between
60.degree. C. and 70.degree. C. to produce shrinkage of the tissue.
Heating of the cornea and/or sclera to a temperature within this
range can also produce softening and/or plasticizing (e.g., to
approximately 10% of the native strength of the tissue). The cornea
and/or sclera can be heated to greater than 80.degree. C. of the
eye to produce denaturation of the tissue.
[0081] The STEM procedure may provide one or more of the following
advantages:
[0082] Increased depth of field of the eye;
[0083] Preservation of distance visual acuity, as the central
corneal and central lenticular regions are substantially unaffected
by the treatment;
[0084] Preservation of limbal stem cells, ciliary muscle function,
conjunctiva, epithelium, and aqueous production, as these are
substantially unaffected by treatment;
[0085] No substantial loss of contrast sensitivity;
[0086] No substantial disturbances of night vision;
[0087] Preservation of aesthetics of the eye, as there are no cuts,
implants, or full punctures of the eye;
[0088] Rapid patient recovery, as the conjunctiva is protected
during treatment;
[0089] Tolerable treatment procedure for many patients;
[0090] Improved safety of the treatment procedure;
[0091] Little additional optical power required, resulting in
substantially no cross blurring; or
[0092] Other surgeries, including additional STEM treatments, are
not precluded.
[0093] FIG. 1 illustrates a presbyopic eye 100 in a configuration
for far vision, in accordance with embodiments. The eye 100
includes a sclera 102, a cornea 104, a pupil 106, an iris 108, and
a lens 110 within a lens capsule, the lens capsule including a lens
capsule anterior surface 112 and a lens capsule posterior surface
114. The sclera is lined by a conjunctiva 116 and includes a sclera
spur 118 adjacent the cornea 104. A ciliary body 120 is adjacent
the ciliary body sclera region 122. The ciliary body 120 is
connected to the lens 110 by vitreal zonules 124 and to the ora
serrata 126 by the posterior vitreal zonules 128 (hereinafter
"PVZ"). A circumlental space 130 (hereinafter "CLS") is defined by
the distance between the lens 110 and the ciliary body 120 along a
lens equator plane 132, the lens equator plane 132 passing through
an equatorial sclera region 134.
[0094] FIG. 2 illustrates the presbyopic eye 100 of FIG. 1
attempting to correct for near vision, in accordance with
embodiments. In the presbyopic eye 100, the curvature of the lens
110 does not change substantially from the curvature in the far
vision configuration, and the accommodative amplitude of the lens
110 along the lens equator plane 132 is relatively small.
[0095] Table 1 shows PVZ mobility and CLS size in non-presbyopic
and presbyopic eyes during an un-accommodative state ("UN-ACC") and
an accommodative state ("ACC"). In non-presbyopic eyes, the length
of the PVZ changes from 4.6 mm in the un-accommodative state to 3.6
mm in the accommodative state, for a net change of 1 mm. In
contrast, PVZ mobility is substantially reduced in presbyopic eyes:
the PVZ length changes from 4.6 mm in the un-accommodative state to
4.45 mm in the accommodative state, for a net change of only 0.15
mm. Additionally, the size of the CLS is significantly smaller in
presbyopic eyes compared to non-presbyopic eyes, with measured
values of 0.68 mm and 0.35 mm in the un-accommodative state, and
0.68 mm and 0.2 mm in the accommodative state, respectively.
TABLE-US-00001 TABLE 1 PVZ mobility and CLS size in non- presbyopic
and presbyopic eyes. Non-Presbyopic Presbyopic UN-ACC ACC Change
UN-ACC ACC Change PVZ (mm) 4.6 3.6 1 4.6 4.45 0.15 CLS (mm) 0.68
0.68 0 0.35 0.2 0.15
[0096] Without being bound to any particular theory, it is believed
that accommodative anterior and inward ciliary apex movement is
hindered by PVZ immobility in the presbyopic eye. The embodiments
disclosed herein can provide improved mobility of the accommodative
anterior and inward ciliary apex movement with softening of the
scleral and corneal tissue as disclosed herein. The embodiments
disclosed herein can provide compensation for antero-posterior lens
growth, equatorial-apex position and zonular insertion angle
changes, and loss in corneal elasticity with age. The embodiments
disclosed herein can provide increased curvature of the lens with
decreased zonular tension in order to provide increased
accommodation. In many embodiments, the simultaneous expansion of
the perilenticular space and softened and/or plasticized
mid-scleral stroma near the ciliary body and PVZ as described
herein can provide for stable distance vision (e.g., augmented by
cross-linking) and restoration (e.g., an increase) of accommodative
amplitude.
[0097] FIG. 3 illustrates stabilization of an eye 100 by
cross-linking to treat presbyopia, in accordance with embodiments.
The stabilized region 136 can be disposed in the outer portion of
equatorial sclera region 134 of the sclera 102. Any suitable
stabilization method, such as collagen cross-linking, can be used
to stabilize the cross-linked region 136 in order to substantially
maintain the outer profile of the sclera 102. In many embodiments,
a cross-linking agent is applied to the sclera and allowed to
infuse into the sclera at stabilized region 136. An energy source
can be applied to the sclera to cross-link the sclera at stabilized
region 136 with the cross-linking agent. The energy source can
include a microelectrode array to generate a patterned cross-linked
profile on the sclera. The energy can include one or more of
thermal energy, radiofrequency (hereinafter "RF") energy,
electrical energy, microwave energy, or light energy.
[0098] In many embodiments, the cross-linking agent includes one or
more of many known chemical photosensitizers in the presence of
oxygen. Oxygen can be delivered to the stabilized region 136 of the
sclera, concurrently with the cross-linking agent or separately.
The cross-linking agent can be exposed to light energy when the
cross-linking agent has been provided to the tissue, in order to
provide cross-linking to a target depth of tissue stabilization.
The light energy may include one or more of visible light energy,
ultraviolet (hereinafter "UV") light energy, or infrared
(hereinafter "IR") light energy. Alternatively or combination, the
cross-linking agent may include a chemical cross-linking agent. In
many embodiments, the cross-linking agent includes one or more of
the following: riboflavin, rose bengal, methylene blue, indocyanine
green, genipin, threose, methylglyoxal, glyceraldehydes, aliphatic
.beta.-nitro alcohols, black currant extract, or an analog of any
of the above.
[0099] FIGS. 4-6 illustrate aspects of a STEM treatment procedure
to expand the CLS and thereby enhance ciliary body apex mobility in
order to increase the accommodative amplitude of the eye, in
accordance with embodiments. The CLS can be expanded by applying
energy to shrink and/or plasticize an inner portion of the eye,
such as the inner portion of the sclera (e.g., the mid-stroma), so
as to move the ciliary body apex outward and thereby increase the
ciliary ring diameter. In many embodiments, the outward movement
includes a radially outward movement away from the optical axis of
the eye and towards a stabilized outer portion of the eye (e.g.,
the cross-linked region 136). The energy to shrink and/or
plasticize the inner portion of the eye can include one or more of
thermal energy, RF energy, electrical energy, microwave energy, or
light energy. The energy can shrink and/or plasticize the tissue by
heating the tissue to a suitable temperature without substantially
weakening the tissue, such as within a range from about 50.degree.
C. to 70.degree. C. Heating the tissue can increase the elasticity
of the tissue. In many embodiments, the heat is applied such that
the outer portion of the tissue remains substantially viable so as
to inhibit post-operative pain and swelling. While in many
embodiments the energy can be applied through the conjunctiva
and/or epithelium, the energy can also be applied with the
conjunctiva and/or epithelium moved away from the sclera. The
energy source can be the same energy source used to cross-link the
eye, as described herein, or a different energy source.
[0100] FIG. 4 illustrates a heat sink 140 placed over the eye 100
of FIG. 3 in order to treat presbyopia, in accordance with
embodiments. The heat sink 140 can be inserted over an outer
portion of the eye 100 including the cornea 104, sclera 102, and
conjunctiva 116, in order to conduct heat away from the outer
portion of the eye 100 during the treatment procedure. The heat
sink can be made of any suitable material. For example, the heat
sink can include a material transmissive to wavelengths of light
energy (e.g., sapphire of diamond-like carbon transmissive to
certain wavelengths of IR light), so that the eye tissue beneath
the heat sink can be heated with absorbed light energy.
[0101] FIG. 5 illustrates a planned treatment zone 142 in the eye
100 of FIG. 4 for treating presbyopia, in accordance with
embodiments. The planned treatment zone 142 can be disposed between
an outer surface 144 (e.g., adjacent the conjunctiva 116) and inner
surface 146 (e.g., adjacent the apex of the ciliary body 120 or a
trabecular meshwork (not shown)) of the equatorial sclera region
134 of an eye 100. The equatorial sclera region 134 has an initial
sclera thickness 148 defined by the distance between outer surface
144 and inner surface 146. The treatment can be applied by a laser
to the treatment region 142 to heat and shrink and/or plasticize
the mid-stroma of the equatorial sclera region 134, thereby causing
the inner sclera surface 146 and inner ciliary body 120 to move in
centrifugal directions 149a, 149b, while avoiding the conjunctiva
116 and ciliary muscles adjacent the ciliary body 120. The laser
can be scanned through the sclera 102 posterior the limbus 150 such
that limbal stem cells and insertions of the rectus muscles of the
eye 100 are avoided.
[0102] FIG. 6 illustrates laser treatment of the eye 100 of FIG. 5
to treat presbyopia, in accordance with embodiments. The laser
treatment can be applied to the treatment zone 142 to shrink and/or
plasticize the tissue in the treatment zone 142 and thereby expand
the CLS 130. Compared to the pre-treatment eye 100 of FIG. 5, the
profile of the outer sclera surface 144 is substantially maintained
(e.g., by stabilization as described herein), while the profile of
the inner sclera surface 146 moves in a centrifugal direction 149a
and is deflected substantially outward, resulting in a decreased
sclera thickness 148 of the equatorial sclera region 134. The
shrinkage of the mid-stroma causes the inner profile of the ciliary
body 120 to move centrifugally outward toward the outer sclera
surface 144, producing an increase in the size of the CLS 130 and
an enhancement in the inward mobility of the ciliary body 120
during accommodation.
[0103] Referring to FIGS. 7 and 8, an enhancement in centrifugal
accommodative and un-accommodative movement of the eye 100 of FIG.
6 is observed following CLS expansion, in accordance with
embodiments. FIG. 7 illustrates the post-operative eye 100 in a
near vision configuration with the lens 110 in an accommodative
state. FIG. 8 illustrates the post-operative eye 100 in a far
vision configuration with the lens 110 in a un-accommodative state.
Mobility of the ciliary body apex has been restored, and
substantial changes in the curvature of the lens 110 and large
accommodative amplitude along the lens equator plane 132 are
observed, in contrast to the presbyopic eye of FIGS. 1 and 2.
[0104] FIG. 9 illustrates treatment of the eye 100 to soften the
sclera proximate the insertion location of the PVZ 128 to treat
presbyopia, in accordance with embodiments. The treatment region
can extend posterior to the lens equator plane 132 and anterior to
the insertion location of the PVZ 128 at the ora serrata 126. The
treatment can be applied to the treatment region to ablate the
tissue and form tiny fenestrations 160 within a scleral softening
region 161 of the sclera 102. Alternatively or in combination, the
tissue can be softened without ablation. In many embodiments, the
PVZ insertion location can be softened order to enhance mobility of
the PVZ and thereby increase the anterior mobility of the ciliary
body apex during accommodation. Any suitable method can be used,
such as laser-induced softening and/or plasticizing, to soften
and/or plasticize any suitable portion of the sclera. The softening
can include heating the portion of the sclera to a suitable
temperature to weaken the tissue, such as within a range from about
70.degree. C. to 90.degree. C. The heat can be applied using
energy, such as one or more of thermal energy, RF energy,
electrical energy, microwave energy, or light energy. The energy
may be emitted by the same energy source used to cross-link the eye
or shrink and/or plasticize the inner portion of the eye, or by a
different energy source. The softening and/or plasticizing
treatment can be applied at any suitable location such that damage
to non-treatment regions of the eye, such as muscles of the eye, is
avoided. For example, the treatment can be applied to soften and/or
plasticize four portions of the sclera, each corresponding to a
location away from muscles of the eye including inferior muscles,
superior muscles, nasal muscles, and temporal muscles. In many
embodiments, after softening and/or plasticizing, the mobility of
the PVZ 128 in accommodated and unaccommodated states is enhanced,
and the anterior movement of the ciliary body apex is restored.
[0105] FIGS. 10-11 illustrate aspects of a STEM treatment procedure
to enhance corneal bending of the eye to treat presbyopia, or
glaucoma, or both, in accordance with embodiments. In many
embodiments, inner portions of the scleral spur and/or the cornea
lateral to the Schlemm's canal and trabecular meshwork can be
heated to increase the elasticity of the eye near the scleral spur
inner portions, thereby enhancing corneal bending during
accommodation to treat presbyopia, for example. For example, energy
can be applied to shrink and/or plasticize the inner portions by
heating the tissue to a suitable temperature without substantially
weakening the tissue, such as within a range from about 50.degree.
C. to 70.degree. C. Alternatively, energy can be applied to soften
the inner portions by heating the tissue to a suitable temperature
to weaken the tissue, such as within a range from about 70.degree.
C. to 90.degree. C. Any suitable energy source can be used to
enhance corneal bending, as described herein. The energy source can
be the same energy source used to cross-link the eye or soften the
PVZ insertion location, as described herein, or a different energy
source, for example.
[0106] FIG. 10 illustrates a planned treatment of the eye 100 of
FIG. 9 to soften the tissue lateral to the Schlemm's canal and
trabecular meshwork to treat presbyopia, in accordance with
embodiments. The Schlemm's canal 170 and trabecular meshwork 172
are positioned within the inner portion of the cornea 104 adjacent
to the scleral spur 118 of the sclera 102. A planned treatment zone
174 can be disposed within the cornea 104 lateral to the Schlemm's
canal 170, trabecular meshwork 172, and scleral spur 118. In many
embodiments, the treatment zone 174 can be located outside the
optically used portion of the cornea 104 (e.g., the peripheral
corneal stroma). Alternatively or in combination, the treatment
zone 174 can be located within a portion of the sclera 102 lateral
to the Schlemm's canal 170 and trabecular meshwork 172, such as the
scleral spur 118. The outer portion of the cornea 104 and/or the
scleral spur 118 lateral to the planned treatment zone 174 can be
cross-linked to create a stabilized outer profile, as previously
described herein.
[0107] FIG. 11 illustrates a heat sink 176 placed on the eye 100 of
FIG. 10 in order to shrink and/or plasticize the tissue lateral to
the Schlemm's canal and trabecular meshwork to treat presbyopia, in
accordance with embodiments. The heat sink 176 (e.g., a chilled
sapphire window) can be placed on the scleral spur 118 to allow
transmission of energy through the heat sink into the treatment
zone 174 and avoid heating of the outer portion of the scleral spur
118, as previously described herein. Energy can be applied to the
eye 100 at the treatment zone 174 in order to heat and shrink
and/or plasticize the tissue as previously described herein,
thereby creating a zone of shrinkage 178 within the cornea 104
lateral to the Schlemm's canal 170 and trabecular meshwork 172. The
treatment can be applied to soften and increase the elasticity of
the cornea 104 and/or scleral spur 118 such that corneal mobility
and asphericity during accommodation is increased, thereby
enhancing the accommodative power of the eye 100.
[0108] Additionally, in many embodiments, the shrinkage and/or
plasticizing can move the tissue of the treatment zone 174 outward,
thereby increasing the cross-sectional size of the Schlemm's canal
170 and/or channels of the trabecular meshwork 172. The expansion
of the Schlemm's canal 170 and trabecular meshwork 172 can
facilitate aqueous outflow of the eye 100, thereby normalizing the
IOP. Accordingly, in many embodiments, the softening and/or
plasticizing of the cornea 104 and/or scleral spur 118 lateral to
the Schlemm's canal 170 and trabecular meshwork 172 as described
herein can also be applied to treat glaucoma. The glaucoma
treatment can be performed in combination with the presbyopia
treatments described herein, or as a separate procedure.
[0109] FIG. 12 is a simplified block diagram depicting steps of a
method 200 of treating an eye for presbyopia, in accordance with
embodiments. Steps 210, 220, and 230 depict embodiments for
stabilization of the anterior sclera, as previously described
herein, for example. Steps 240 and 250 depict embodiments for
expansion of the CLS, as previously described herein, for example.
Step 260 depicts embodiments for softening of the PVZ insertion
location, as previously described herein, for example. Step 270
depicts embodiments for enhancing corneal bending, as previously
described herein, for example.
[0110] In step 210, the anterior sclera is soaked with riboflavin
and 100% oxygen, for example. Although reference is made to 100%
oxygen, the amount of oxygen applied to the eye can be less than
100% and often comprises an amount of oxygen greater than
atmospheric oxygen, for example greater than about 20%. In many
embodiments, the riboflavin is a 0.1 or 0.2% riboflavin solution.
For example, IR laser-assisted conjunctival spotting can be used to
soak the riboflavin into the anterior sclera for approximately 5
minutes. Alternatively or in combination, a microneedle array can
be used to soak the riboflavin solution for approximately 10
minutes.
[0111] In step 220, the anterior sclera is exposed to blue light to
cross-link the anterior sclera, as previously described herein. In
many embodiments, the blue light is applied at an intensity of
greater than 30 mW/cm.sup.2. For example, the light can be applied
at 50 mW/cm.sup.2. The light can be applied for approximately 5
minutes in a suitable pattern. For example, a ring donut pattern
with an inner diameter of 13 mm to 18 mm can be used in order to
mask the cornea and limbus of the eye.
[0112] In step 230, the eye is rinsed with saline.
[0113] In step 240, a chilled scleral contact lens is placed over
the eye to direct heat away from the outer portion of the eye, as
previously described herein. The contact lens can be chilled to any
suitable temperature, such as 4.degree. C.
[0114] In step 250, the CLS is expanded by scanning an IR or mid-IR
laser in the equatorial sclera region to cause thermal shrinkage
and/or plasticizing of the tissue, as previously described herein.
The laser can have any suitable emission wavelength, such as within
a range of approximately 1.4 .mu.m to 10 .mu.m. In many
embodiments, the laser emission wavelength can be one of the
following: 1.48 .mu.m, 1.54 .mu.m, 2.01 .mu.m, or 6.1 .mu.m. Any
suitable scanning pattern can be used, such as a continuous
360.degree. circle around the eye, or discontinuous quadrant arcs
(e.g., to avoid the insertion zones of the recti muscles). A finite
element analysis of suitable portions of the eye (e.g., the ciliary
body, lens, or vitreous zonules) can be used to determine a
suitable scanning pattern. The scanning procedure can take
approximately three to four minutes. In many embodiments, the laser
can be scanned from 3 mm to 7 mm posterior to the limbus, to avoid
limbal stem cells and recti, and is applied to the mid-stroma of
the sclera only, to avoid the epithelium, conjunctiva, and ciliary
muscles. The mid-stroma of the sclera can be heated to
approximately 60.degree. C. to increase scleral elasticity and
shrink and/or plasticize the mid-stroma within a range of 100 .mu.m
to 250 .mu.m of shrinkage, and thereby increase the ciliary apex
ring diameter by approximately 400 .mu.m and the size of the CLS
within a range of 200 .mu.m to 500 .mu.m. The inward mobility of
the ciliary body can be enhanced post-treatment by approximately
250 .mu.m.
[0115] In step 260, the PVZ insertion location is softened and/or
plasticized by scanning an array of spots is scanned in the sclera
near the ora serrata with an IR or mid-IR laser, as previously
described herein. The laser can be any suitable laser with any
suitable emission wavelength, as described herein. Any suitable
scanning pattern can be used, such as discontinuous quadrant arcs
(e.g., to avoid the recti muscles). The scanning procedure can take
approximately three to four minutes. In many embodiments, each spot
in the array has a diameter ranging from 50 .mu.m to 1 mm in
diameter. For example, each spot can have a 100 .mu.m spot diameter
and approximately 250 .mu.m sclera depth. The spots can form tiny
fenestrations of approximately 50% sclera depth in the treatment
region. The array can be scanned 3 mm to 7 mm posterior to the
limbus (e.g., between the ora serrata and the anterior ciliary
body). The softening and/or plasticizing can be applied such that
excessive bleeding and coagulation of surface conjunctiva blood
vessels is avoided. In many embodiments, PVZ mobility and anterior
ciliary body apex movement is enhanced post-treatment by
approximately 1 mm.
[0116] In step 270, corneal bending is enhanced by scanning an IR
or mid-IR laser is scanned near the scleral spur to cause thermal
shrinkage, as previously described herein. The laser can be any
suitable laser with any suitable emission wavelength, as described
herein. Any suitable scanning pattern can be used, such as a
continuous 360.degree. circle around the eye, or discontinuous
quadrant arcs (e.g., to avoid the insertion zones of the recti
muscles). The scanning procedure can take approximately one
minute.
[0117] Although the above steps show method 200 of treating an eye
in accordance with embodiments, a person of ordinary skill in the
art will recognize many variations based on the teaching described
herein. Some of the steps may comprise sub-steps. Many of the steps
may be repeated as often as beneficial to the treatment. One or
more steps of the method 200 may be performed with any suitable eye
treatment system, such as the embodiments described herein. Some of
the steps may be optional, such as one or more of steps 210, 220,
or 230. The order of the steps can be varied. For example, steps
250, 260, and 270 may be performed in any suitable order.
[0118] The processor of the treatment apparatus as disclosed herein
can be configured with one or more instructions to perform the
method 200 and/or any one of the steps and sub-steps of the method
200. The processor may comprise memory having instructions to
perform the method, and the processor may comprise a processor
system configured to perform the method for example. In many
embodiments the processor comprises array logic such as
programmable array logic (hereinafter PAL), configured to perform
one or more steps of the method 200, for example.
[0119] FIG. 13 illustrates a MRI of a non-presbyopic eye 300 in a
far vision configuration, in accordance with embodiments. The lens
302 is in an un-accommodative state and exhibits a flattened shape.
The eye 300 has a relatively increased CLS 304 compared to the near
vision configuration, described below.
[0120] FIG. 14 illustrates a MRI of a non-presbyopic eye 300 in a
near vision configuration, in accordance with embodiments. The lens
302 is in an accommodative state and exhibits significant changes
in curvature and location compared to the far vision configuration
of FIG. 13. The CLS 304 is reduced compared to the near vision
configuration of FIG. 13.
[0121] FIG. 15 illustrates a video image of laser treatment to
shrink scleral tissue, in accordance with embodiments. A laser is
applied to the tissue to cause the marker vessel and local tissue
400 to shrink and migrate in the direction indicated by arrow 402
at an initial time 403.
[0122] FIG. 16 illustrates the video image of FIG. 15 at a later
time 403, in accordance with embodiments. Laser irradiation is
applied at subsurface treatment spot 404. The marker vessel and
local tissue 400 have shrunk and migrated towards the treatment
spot 404 along direction 402.
[0123] FIG. 17 illustrates the video image of FIG. 17 at a later
time 403, in accordance with embodiments. The marker vessel and
local tissue 400 continue to shrink and migrate towards treatment
spot 404.
[0124] FIG. 18 illustrates the video image of FIG. 17 at a later
time 403 showing involution of the marker vessel and tissue 400
into the laser irradiation treatment spot 404, in accordance with
embodiments.
[0125] Based on the teachings disclosed herein, a person of
ordinary skill in the art can configure the treatment energy to
shrink the inner portion as described herein.
[0126] FIG. 19 illustrates a plot of UNVA versus IOP for patients
pre- and post-STEM treatment, in accordance with embodiments. The
UNVA is represented by a logarithm of the minimal angle of
resolution (hereinafter "log MAR") for UNVA. Pre-STEM treatment
data points are represented by diamonds. Post-STEM treatment data
points are from a one year follow-up after the STEM procedure as
described herein was performed and are represented by squares.
Post-STEM patients exhibit reduced IOP values compared to pre-STEM
patients. UNVA is also improved in post-STEM patients, as indicated
by lower log MAR UNVA values compare to pre-STEM patients. A
significant number of post-STEM patients have IOP values of 15 mm
Hg or less, and visual acuity score of Jaeger 4 (hereinafter "J4")
or better, as indicated by the data points lying on and within the
boundary 500.
[0127] FIG. 20 illustrates a system 600 for treating an eye 602, in
accordance with embodiments. The system 600 includes a processor
604 having a tangible medium 606 (e.g., a RAM). The processor 604
is operatively coupled to a first light source 608, a second light
source 610, and a third light source 612. The first light source
608 emits a first beam of light 614 that is scanned by X-Y scanner
616 through an optional mask 618 and optional heat sink 620 onto
the eye 602. The mirror 622 directs light energy from the eye 602
to a viewing camera 626 coupled to a display 628. An independent
non-treatment light source for the viewing camera can be provided,
for example. The mirror 622 may direct a portion of the light beam
returning from eye 602 to the camera 626, for example. The second
light source 610 emits a second beam of light 630 that is combined
by a first beam combiner 632 with the first beam of light 614 prior
to passing through X-Y scanner 616. The third light source 612
emits a third beam of light 634 that is combined by a second beam
combiner 636 with the second beam of light 630 prior to passing
through the first beam combiner 632.
[0128] In many embodiments, the beams of light 614, 630, and 634
can be scanned onto the eye 602 at a specified X and Y position by
the X-Y scanner 616 to treat the eye 602. The X-Y scanner can be
configured to scan the combined light beams onto the eye 602 in a
suitable treatment scan pattern, as previously described herein. An
optional mask 618 can be used to mask the light applied to the eye
602, for example, to protect masked portions of the eye 602 while
treating other portions as described herein. An optional heat sink
620 can be placed on the eye 602 during treatment to avoid heating
specified portions of the eye 602, as previously described
herein.
[0129] The system 600 can be used to apply light energy to the eye
602 in accordance with any suitable treatment procedure, such as
the embodiments described herein. In many embodiments, the first
light beam 614 has a first wavelength, the second light beam 630
has a second wavelength, and the third light beam 634 has a third
wavelength. Each wavelength can be a different wavelength of light.
Alternatively, at least some of the wavelengths can be the same.
For example, in accordance with the embodiments described herein,
the first light beam 614 can have a wavelength suitable to:
cross-link an outer portion of the eye 602 and shrink an inner
portion of the eye 602; shrink the inner portion and cross-link the
outer portion concurrently; shrink the inner portion after the
outer portion has been cross-linked; or any suitable combinations
thereof. Alternatively, the first light beam 614 can have a first
wavelength suitable to cross-link the outer portion of the eye 602,
as previously described herein, and the second light beam 630 can
have a second wavelength suitable to shrink the inner portion of
the eye 602, as previously described herein. The third light beam
634 can have a third wavelength suitable to soften a portion of the
sclera of the eye 602, as previously described herein. Any suitable
combination of wavelengths of light for applying any combination of
the treatments described herein, concurrently or separately, can be
used.
[0130] FIGS. 21A and 21B illustrate mask pattern 700 and treatment
scan pattern 710, respectively, suitable for combination with the
treatments described herein, in accordance with embodiments. Any
suitable system can be used to apply the mask pattern 700 and
treatment scan pattern 710, such as the treatment system 600. For
example, mask pattern 700 and treatment scan pattern 710 can be
used to selectively soften portions of the sclera, such as in step
260 of method 200. The mask pattern 700 can be applied to the eye
by any suitable mask, such as the optional mask 618 of system 600.
The mask pattern 700 can be used to protect portions of the eye
under masked regions 702 and allow softening of portions of the eye
under transmissive regions 704, as previously described herein. The
treatment scan pattern 710 can be applied by any suitable system,
such as by the system 600 using X-Y scanner 616. The treatment scan
pattern 710 can be used to form four quadrants of laser spots 712
on the sclera to soften the sclera, as previously described
herein.
[0131] FIG. 22 illustrates an OCT image of a subsurface laser
treatment of a cornea 800 suitable for combination with the
treatments described herein, in accordance with embodiments. The
cornea 800 includes the Bowman's membrane 802. Subsurface laser
treatment (e.g., using a medium intensity laser) is applied to the
treatment regions 804 posterior to the Bowman's membrane 802, such
that subsurface shrinkage of the corneal tissue at treatment
regions 804 occurs. The subsurface shrinkage can be used to reshape
(e.g., flatten) the cornea 800 and the Bowman's membrane 802 to
treat the eye.
[0132] FIGS. 23A-D illustrate images of a cornea 850 of an eye
treated with a hollow microelectrode array suitable for combination
with the treatments described herein, in accordance with
embodiments. FIG. 23A illustrates an OCT image of the cornea 850
including the Bowman's membrane 852. FIG. 23B illustrates an image
of the fluorescein stain pattern 853 of the eye of FIG. 23A. FIG.
23C illustrates an OCT image of the cornea 852 as in FIG. 23A with
increased grey levels. FIG. 23D illustrates a fluorescence image of
the eye of FIG. 23A. The hollow microelectrode array can be applied
to the cornea to produce a patterned corneal shrinkage profile such
as the corneal shrinkage profile 854. For example, in many
embodiments, the hollow microelectrode array can be used to apply
energy (e.g., light energy) to a cross-linking agent (e.g., a
chemical photosensitizer such as riboflavin) in order to stabilize
selected portions of the cornea (e.g., through collagen
cross-linking) to maintain a desired corneal surface profile. Any
suitable method and cross-linking agent previously described herein
in the context of cross-linking of the sclera can be used to
cross-link the cornea.
[0133] FIGS. 24A and 24B show a treatment apparatus 900, in
accordance with embodiments. The apparatus 900 comprises one or
more components as described herein and configured to perform
treatment as described herein, and can be combined in one or more
of many ways in accordance with embodiments described herein, for
example with reference to one or more components of FIG. 20. The
treatment apparatus 900 comprises a chin rest 902 and head rest 903
to support the head of the patient 904. The laser delivery system
906 comprises a treatment energy source such as an infrared laser
source 908, an alignment laser 909 such as a visible laser, a
fixation light 910 such as an LED, a scanner 912, a foot switch
914, an energy detector 916, a computer display monitor 918, a
chiller 920, a cooling lens assembly 922, and a camera 924 coupled
to a processor 926. The processor comprises one or more
instructions of a treatment program embodied on a tangible medium
such as a computer memory or a gate array in order to execute one
or more steps of a treatment method as disclosed herein.
[0134] The treatment apparatus 900 comprises a laser delivery
system 906 to treat the patient. Beam splitters 928 can be provided
along the optical path to align the infrared laser beam 930 from
the infrared laser 908 with the alignment laser beam from the
alignment laser 909, such that the treatment beam extends coaxially
with the visible alignment beam toward an eye 932 engaged with the
docking station 933. A scanner 912 can be provided to scan the
laser beam 930 in a desired pattern on the eye 932 as disclosed
herein. A temperature sensor 934 can be coupled to the processor
926 and the cooling lens assembly 922 to allow treatment when the
cooling lens assembly 922 comprises a temperature to cool the
conjunctiva as disclosed herein. The detector 916 can measure the
energy of the treatment energy beam in order to adjust the laser
beam energy to provide a treatment to the eye 932 as disclosed
herein. The patient 904 can view the fixation LED 910 in order to
align the eye 932. The visible camera 924 can be coupled to the
processor 926 to display an image of the eye 932 to a user 936
(e.g., a surgeon), for example with a real time display on monitor
918. Alternatively or in combination, the user 936 can view the eye
932 with eye pieces 938 of an operating microscope, for
example.
[0135] The laser system 906 comprises components coupled to the
processor 926 and the processor 926 comprises instructions to treat
the patient 904 in accordance with embodiments described herein.
The laser 908 is coupled to a foot pedal 914 for the operator 936
to treat the eye 932 with the laser beam 930. A joystick 940 can be
coupled to a X,Y,Z stage 942 of a slit lamp base to position the
laser and imaging system in relation to the patient 904.
Alternatively or in combination, the joystick 940 can be coupled to
the scanning optical system to direct the treatment to a desired
location of the eye 932. The processor 926 comprises instructions
to scan the laser beam 930 with an intensity on the eye 932 to
provide softening of the stroma as described herein.
[0136] FIG. 25A shows a treatment region 1000 of the sclera 1002
and conjunctiva 1004 under a heat sink comprising a cooling lens
1006 contacting the conjunctiva 1004. The cooling lens structure
1006 can provide one or more intact layers of epithelium 1003 above
the conjunctiva 1004 and treatment zone 1000 when tissue has been
relocated as described herein, in order to provide presbyopia and
or glaucoma treatment and to inhibit regression of effect.
Maintaining one or more layers of epithelium 1003 can provide
improved an improved protective barrier function of the eye. The
cooling lens structure 1006 comprises a material that is optically
transmissive to the one or more wavelengths of light used to heat
and soften the scleral tissue. The treatment laser beam 1008 can be
transmitted through the cooling structure 1006 such that the
treatment laser beam 1008 irradiates an upper surface of the
epithelium 1003 of the conjunctiva 1004, and the epithelium 1003 of
the conjunctiva 1004 may comprise a lower basal cell layer, an
intermediate wing cell layer and an upper squamous layer. In many
embodiments, these layers of the epithelium 1003 transmit a
sufficient amount of energy of the treatment beam to provide at
least partial penetration of the laser beam into the scleral tissue
of the eye.
[0137] FIG. 25B shows a region of the conjunctiva 1004 above the
scleral softening treatment region as in 25A comprising an intact
epithelial layer 1003 subsequent to delivery of laser energy with
the optically transmissive heat sink contacting the tissue. One or
more layers of the epithelium 1003 above the conjunctival stroma
1016 such as one or more of the basal 1010, wing 1012, or squamous
1014 layers of epithelium 1003 remains intact over at least a
portion of the treatment zone to provide improved comfort and
retained efficacy of treatment in many embodiments.
[0138] FIG. 26A shows a tissue depth penetration profile 1100 of a
laser beam. In many embodiments, the laser beam comprises a tissue
absorbance such that the 1/e depth is about 100 micrometers (um).
The percentage irradiance of the tissue decreases exponentially
from about 100% near the outer surface tissue to about 37% (1/e) at
a distance within the conjunctiva of the tissue, for example at a
distance of about 100 um from the surface of the conjunctiva. In
many embodiments, greater than half of the electromagnetic energy
of the laser beam is absorbed with the conjunctiva, and the scleral
stroma comprises a treatment temperature greater than the
conjunctiva. While the laser beam may comprise one or more of many
wavelengths as described herein, in many embodiments the laser beam
comprises an infrared laser beam such as an infrared laser beam
having a wavelength of about 6.1 um, for example.
[0139] FIG. 26B shows a tissue heating profile 1200 with scanning
of a laser beam as in FIG. 26A, including initial and treatment
curves 1202, 1204. The temperature of the outer surface of the eye
can be decreased with one or more of a heat sink or cooling, for
example. The outer surface of the eye can be cooled to a desired
temperature with the contact cooling structure, and the eye
treated. The chilled heat sink structure can be chilled to a
temperature within a range from above the freezing temperature of
saline at about -3 degrees Celsius (C) to below ambient room
temperature of about 20 degrees Celsius. Alternatively, a heat sink
can be provided without chilling. Alternatively, a heat sink can be
provided without chilling, for example when the ambient temperature
comprises about 20 degrees C. The eye can be treated with the
scanning laser beam comprising a tissue absorption profile as shown
in FIG. 26A, in order to provide softening of the scleral tissue at
a depth. As heat can be conducted away from the conjunctiva with
the heat sink, the inner portion of the eye comprising the scleral
stroma comprises a temperature greater than the outer conjunctiva.
The depth profile of the heating of the eye can be controlled to
inhibit damage to the ciliary body and choroid when the scleral
stroma is softened as described herein.
[0140] The treatment temperature profiles of FIGS. 26A and 26B can
be used in combination with tissue treatment patterns as disclosed
herein, and the treatment profiles can be used to treat presbyopia,
or glaucoma, or both for example. For example, the treatment
profiles can be used in combination with reference to FIGS. 9 and
21B, and the softened tissue of the sclera can extend a majority of
the distance from the sclera of the lens equator plane to the
scleral location proximate the ora serrata corresponding to the
insertion of the posterior vitreous zonules as described herein. In
many embodiments, the scleral softening region comprises a majority
of the distance between the lens equator and the ora serrata in
each of the plurality of four quadrants of treatment. The scleral
softening region extending the majority of the distance can be
located closer to the ora serrata than the plane of the lens
equator, for example.
[0141] The sclera can be softened as described herein in one or
more of many ways in order to encourage movement of the posterior
vitreous zonules at least anteriorly in order to provide improved
accommodation, such as with one or more of light energy, ultrasound
energy, electrical energy, heating, electroporation or
optoporation, for example. The softening may include micro needle
arrays (hereinafter "MNAs") for adjunct drug delivery following or
before canal or trabecular meshwork expanding scleral translocation
elastomodulation (STEM), for example. Alternatively or in
combination photonic desincrustation or galvanic desincrustation
can be used to remove stiff scleral tissue structures or molecules,
for example. In some embodiments, photoporation can be used in
accordance with embodiments disclosed herein. These alternative
energy sources and tissue treatments are suitable for combination
in accordance with embodiments disclosed herein and can be used to
provide scleral softening to treat presbyopia or glaucoma, or both,
for example.
[0142] Although reference is made to softening scleral tissue with
cross-linking, in many embodiments the scleral softening can be
performed without cross-linking to treat one or more of presbyopia
or glaucoma.
[0143] Although reference has been made to trans-conjunctival
treatment of the sclera with energy delivery through the
conjunctiva, in some embodiments the conjunctiva can be incised to
provide access to the scleral tissue and treatment of the scleral
tissue with energy in accordance with embodiments disclosed
herein.
[0144] FIG. 27A shows absorbance spectra 1300. The absorbance
spectra show the absorbance of corneal stroma and stromal
components saline and protein, in which the protein comprises
collagen. A first absorbance peak appears at about 3 um wavelength,
stroma and saline have a very strong absorbance of about 0.8 per um
of tissue, and the protein comprising collagen is much lower. A
second absorbance peak appears at about a 6.1 um wavelength, and a
third at about a 6.5 um wavelength. The absorbance of stroma of
about 0.3 per um of tissue is stronger than the absorbance of
saline of about 0.22 per um of tissue, both of which are stronger
than the absorbance of protein of about 0.06 per micron of tissue.
The relatively stronger absorbance ratio of stroma and collagen to
saline at about 6 um as compared to absorbance ratios of stroma and
collagen to saline at about 3 um can provide an improve tissue
treatment. The absorbance spectra show stroma having a higher
absorbance than saline at a wavelength of about 6 um. The higher
absorbance of saline at about 6 um can be suitable for treatment in
accordance with embodiments disclosed herein, and can provide an
improved delivery of laser energy to the stroma.
[0145] FIG. 27B shows absorbance spectra in accordance with
embodiments. The absorbance spectra show the absorbance of water,
gelatin with a water concentration of zero (Cw=0) and gelatin with
a water concentration of 80 percent by weight (Cw=80). At about 6
um, both gelatins and water have similar absorbance of about 3000
per cm (0.3 per um). At about 6.4-6.5 um, gelatin with Cw=0 has an
absorbance of about 1500 per cm, gelatin with Cw=80 has an
absorbance of 500 per um and water has an absorbance of about 400
per um.
[0146] Gelatin comprises substantial amounts of collagen and may
comprise a material suitable for modeling absorbance of ocular
tissue such as the stroma, sclera, cornea and conjunctiva, for
example.
[0147] In many embodiments, the wavelength of light used to
irradiate tissue comprises a substantial amount of absorption of
non-water components of the eye such as protein, glycoprotein and
nutrients, for example. In many embodiments, the non-water
components of the eye comprise at least about 10% of the
absorbance, for example at least about 20% of the absorbance, for
example 30%, 40%, 50%, or more of the absorbance, in order to
provide tissue softening, for example.
[0148] FIG. 28 shows a user interface in accordance with
embodiment. The user interface comprises several fields for user's
input data and these input fields comprise inputs which can be used
to control and configure the laser system. The user interface also
includes several outputs and output images which allow the user to
confirm that the system is operating correctly. The system
comprises a screen, which shows a planned treatment. The screen
showing the planned treatment, comprises meridians, such as the 0
degree meridian, the 180 degree meridian, the 90 degree meridian,
and the 270 degree meridian. The treatment screen with the planned
treatment comprises four quadrants, as described herein.
[0149] The user interface comprises several fields for the user to
input the scanned treatment. The scanned treatment may comprise a
number of treatment steps. The treatment steps may comprise a
plurality of treatment patterns. The treatment patterns may
comprise, for example, an annulus. The treatment steps may be
applied sequentially or together, for example. Each of the
treatment steps can be provided with a step number of a treatment
table. The treatment table may comprise of plurality of steps, for
example, step 1 to step 45, as shown on the display of FIG. 28,
step #25 is shown, for example, within the configuration of the
input. Step #45 comprises an annulus as shown, the start diameter
is at 10 millimeters, which can be varied by user input. There is
also an angle that can be offset with an arc start and an arc end.
The angle can start at 0 degrees, and end at 360 degrees, for
example. Each of the steps can be repeated, with a number of
revolutions, for example, two full revolutions of 360 degrees of
the treatment pattern with the corresponding area as shown on the
image of the treatment pattern, for example.
[0150] Alternatively or in combination, refractive treatment can be
entered, for example, a refractive treatment in diopters if
helpful.
[0151] The scan speed can also be set, for example, the scan speed
can be set in millimeters per second, in the embodiment shown, the
scan speed has been selected to 5 millimeters per second, although
the speed can range from any number of values such as a fraction of
a millimeter per second, to over a meter per second, for
example.
[0152] The power of the laser beam is specified in milliwatts, for
example, 250 milliwatts, for a continuous wave system.
Alternatively, the power can be specified for a post-laser system,
and the power can be specified as an energy per pulse, or
alternatively, the power can be specified as an energy of the laser
beam pulses applied per unit time, alternatively or in combination,
the laser beam pulse energy can be specified in the frequency of
the laser beam pulses specified in order to define the power of the
treatment.
[0153] The user interface screen also comprises an inter-step delay
which can be applied between each step so as to provide a
beneficial result, for example, in order to provide healing and
help healing and in order to inhibit damage to the tissue. The
inter-step delay can be specified in milliseconds and can be, for
example, 50 milliseconds as shown alternatively, the delay can be 1
millisecond, 0 milliseconds, 100 milliseconds, or a second, for
example.
[0154] The treatment center can be offset. The treatment center
offset can be specified in x and y millimeters with a coordinate
reference system. Alternatively, the treatment offset can be
specified in angular degrees and with a radio component, for
example. In the screen shown, the treatment center offset can be
specified as an x value in millimeters and a y value in millimeters
for example. In which case the x offset would correspond to the 0
and 180 degree meridians as shown, and the y offset to the 90 and
270 degree meridians as shown.
[0155] A time of the step can be calculated or input by the user,
and the time in milliseconds for example, can be 12,566
milliseconds, which corresponds to approximately 12.5 seconds. The
total energy applied can also be provided for the user to provide a
beneficial treatment, for example, the total energy of 3,142
millijoules, for example.
[0156] As shown in FIG. 28, the image of the treatment plan shown
on the display may comprise one or more markers suitable to provide
a reference with respect to the eye to be treated. For example, a
plurality of concentric rings can be shown, such as the rings are
aligned about an axis of the eye for example, an axis, an optical
axis of the eye. In many embodiments, the plurality of rings
comprises a ring sized to mark the limbus of the eye such that
during treatment, the ring can be aligned with the limbus of the
eye. In many embodiments, the plurality of rings can be evenly
spaced, for example, with increments of 5 millimeter diameter. For
example, two rings can be provided inwardly of the limbal marker
ring. A first ring at 5 millimeters and a second ring at 10
millimeters. Outward of the marking ring of the limbus, a first
ring can be provided at about 15 millimeters and a second ring at
about 20 millimeters in diameter. As shown in FIG. 28, the
treatment of the scleral tissue outward of the limbus corresponds
to treatment aligned with the outer two rings at dimension of
approximately 15 millimeters to about 23 millimeters diameter.
[0157] The user interface may comprise a treatment status area on
the display. The treatment progress can be showed with a step and a
time at which the step was finished, for example. A treatment time
which is the actual treatment time in seconds, a total treatment
time, for example, a chiller temperature, a power temperature, and
then elapsed time in the centration can be offset as noted above.
The laser system in treatment apparatus as described herein is
suitable for combination with one or more of many types of surgery.
For example, surgery to treat glaucoma as described herein, such as
posterior open angle glaucoma (hereinafter "POAG"), and in many
embodiments may be combined with corneal refractive surgery. For
example, with reshaping of the stromal tissue of the cornea.
[0158] When the desired treatment has been determined, the
treatment may be modified, for example, by adding or removing
treatment steps with an add treatment step button to provide an
even more improved treatment. And additional steps can be added or
deleted as appropriate.
[0159] When a desired treatment has been verified to be appropriate
by the user, the treatment steps can be loaded onto a system
controller or alternatively, treatment can be saved with the save
treatment steps button, or alternatively the planned treatment can
be removed from the screen with the clear treatment steps.
[0160] FIG. 29 shows array ultrasound transducer array circuitry
1500 to treat tissue. The ultrasound circuitry may comprise one or
more components of the treatment apparatus as described herein. The
transducer array can be configured to treat the eye in a manner
similar to the light energy as described herein, in order to treat
one or more of presbyopia or glaucoma.
[0161] The transducer array can be configured to treat tissue near
the surface of the eye and provide a treatment profile as described
herein. Alternatively or in combination, the circuitry can be
configured to treat the eye beneath the sclera.
[0162] In many embodiments, the transducer array is configured to
treat the posterior vitreous zonule in order to increase
accommodation. The transducer array can be configured with a time
and corresponding phase delay so as to provide a spherical
ultrasound wave directed toward the targeted tissue. The transducer
array can be configured such that a virtual spherical wave
corresponding to time variations and phase variations of the
transducer array is provided. The circuitry of the ultrasound
system can be configured to provide the focused ultrasound beam to
focus energy on the posterior vitreous zonules, for example.
[0163] In many embodiments, the ultrasound transducer array is
configured to treat a posterior vitreous zonule. The circuitry and
transducer array, and can be configured to release tension of the
posterior vitreous zonule in order to provide increased movement of
the lens of the eye. Alternatively or in combination, the
transducer array can be configured to ablate the posterior vitreous
zonule in order to provide increase accommodative amplitude of the
eye. In some embodiments, an ultrashort pulsed laser such as a
femto second laser can be used to incise the posterior vitreous
zonule in order to increase accommodation.
[0164] Alternatively or in combination with treatment, the
ultrasound apparatus can be used to image the eye.
[0165] The ultrasound transducer array may comprise one or more
commercially available components known to a person of ordinary
skill in the art, such as components commercially available from
Maxim Integrated Circuits, and as described in Figures 5 and 6 of
the Maxim tutorial 4038 Optimizing Ultrasound-Receiver VGA
Output-Referred Noise and Gain: Improves Doppler Dynamic Range and
Sensitivity, available on the World Wide Web at
maximintegrated.com, for example.
[0166] FIGS. 30A to 30D show ultrasound bio-microscopy (hereinafter
"UBM") of eyes in accordance with embodiments.
[0167] FIG. 30A shows a non-presbyopic eye in unaccommodated state
in accordance with embodiments. In the unaccommodated state, the
posterior vitreous zonule can be seen in the image shown, and the
posterior vitreous zonule extends from an insertion at the ora
serrata posteriorly to an anterior insertion near the apex of the
ciliary body. In many embodiments, the posterior vitreous zonule is
connected to the tissue of the ciliary body at the ora serrata, and
the ciliary body can be seen to be moved anteriorly when the eye
accommodates.
[0168] FIG. 30B shows a non-presbyopic eye as in FIG. 30A in an
accommodated state. The ciliary body can be seen to move anteriorly
and inward with respect to the ciliary body as shown in FIG. 30A.
In addition, the posterior vitreous zonule can be seen to move
anteriorly on the eye. This anterior movement of the posterior
vitreous zonule at the insertion into the ora serrata allows
accommodation. The posterior vitreous zonule may comprise some
substantially fixed length with the eye accommodates. In many
embodiments, the posterior portion of the posterior vitreous zonule
is connected to the ciliary body near a posterior most portion of
the ciliary body. The ciliary body where the posterior vitreous
zonule connects can be seen to slide anteriorly in order to allow
movement of the lens of the eye during accommodation. For example,
when the posterior vitreous zonule comprises a substantially fixed
length.
[0169] The above described images and model and corresponding model
can be used to provide improved treatments for accommodation in
accordance with embodiments disclosed herein. For example, the
softening of the eye can be provided in order to allow anterior and
inward movement of the ciliary body, and anterior movement of the
posterior vitreous zonule. For example, the scleral tissue between
the ora serrata and the apex of the ciliary body can be softened in
order to allow movement of the posterior vitreous zonule and
ciliary body anteriorly. Alternatively or in combination, in some
embodiment, the posterior vitreous zonule can be treated in order
to allow the posterior vitreous zonule to stretch.
[0170] FIG. 30C shows a presbyopic eye in an unaccommodated state
in accordance with embodiment. The posterior vitreous zonule can be
seen to move anteriorly when the eye accommodates. However, the
posterior vitreous zonule and corresponding ciliary body tissues do
not move as far anteriorly.
[0171] FIG. 30D shows a presbyopic eye in an accommodated state in
accordance with embodiment. In the accommodated state the
presbyopic eye, the anterior movement of the posterior vitreous
zonule is inhibited with respect to the non-presbyopic eye with
reference to FIG. 30D, a person of ordinary skill in the art will
recognize the movement interiorly of the posterior vitreous zonule
is inhibited. In addition, movement of the ciliary body inward to
provide accommodation is also inhibited.
[0172] The treatments as disclosed herein are well suited to
provide a treatment of a presbyopic eye with decreased
accommodation as in FIGS. 30C and 30D, and provide improved
accommodation with movement of the eye having similarity to the
accommodative movement of the eye shown in FIGS. 30A and 30B. For
example, the scleral softening, the profile changes and softening
of the posterior vitreous zonule may comprise components of the
treatment, either alone or in combination as disclosed herein.
[0173] Experimental Studies
[0174] In accordance with embodiments described herein, a person of
ordinary skill in the art can conduct experiments to determine
methods, treatments parameters and system configurations to treat
presbyopia.
[0175] Eyes can be treated in accordance with embodiments disclosed
herein, such as treatment energies and times to provide treatment
profiles in accordance with embodiments disclosed herein.
[0176] In the presbyopic eye, the sclera may bow inward in the
region of the scleral spur thereby changing the inner contour of
the muscle/zonule complex and the circumlental space is reduced,
such that the presbyopic eye may be suitable for treatment in
accordance with embodiments. The amount of circumlental space can
be directly correlated with accommodative amplitude. In many
embodiments shrinking and strengthening the sclera in the region of
the lens equator plane restores the sclera/muscle geometry and
restore the circumlental space in the aged eye in order to increase
accommodation and treat glaucoma, in accordance with embodiments
disclosed herein. Modification of the ocular geometry toward that
of the young eye can restore some accommodative amplitude, in
accordance with embodiments.
[0177] Magnetic resonance imaging (MRI) studies can be conducted on
eyes in accordance with the studies of Strenk and colleagues, in
order to assess the amount of accommodation provided with the STEM
procedure as disclosed herein.
[0178] The magnetic resonance imaging (MRI) studies of Strenk and
colleagues and the Modified Geometric Theory (MGT) of presbyopia
development are suitable for incorporation in accordance with
embodiments, can be used to determine suitable treatment parameters
and can be used to determine treatment parameters in accordance
with the mechanism of presbyopia and these MRI findings.
[0179] MRI has the ability to provide unique biometric information
from the intact human eye during accommodation and with
accommodation at rest. These images of the anterior segment can be
free of optical or acoustic distortions. Additionally, MRI can
acquire sets of images in any desired plane or planes. MRI also
offers soft tissue contrast. Also, MRI allows visualization of
structures normally hidden by the iris. Ciliary muscle contraction
is essentially undiminished throughout life for both phakic and
pseudophakic eyes. A changing geometric relationship between the
accommodative structures and lifelong lens growth appear to cause
an upward and inward ciliary muscle displacement. This results in
decreased circumlental space, in many embodiments concomitant with
decreased zonular tension, and increased stresses throughout the
uveal tissue. In many embodiments, the crystalline lens
cross-sectional area is reduced during relaxed accommodation when
zonular tension is greatest and the lens material can be slightly
compressed. The Modified Geometric Theory (hereinafter "MGT") of
Strenk and colleagues can be incorporated in accordance with
embodiments disclosed herein. In accordance with embodiments
disclosed herein the MGT, lens hardening is not the cause of
presbyopia, and lens hardening that occurs with age can be an
effect of presbyopia. In accordance with embodiments, the MGT
attributes presbyopia to the changing geometric relationship
between the ciliary muscle, the zonular apparatus, and the lens.
This changing geometry is brought about by lifelong lens growth
that results in ciliary muscle displacement and reduced
circumlental space, suitable for treatment in accordance with
embodiments disclosed herein. With advancing age and decreasing
circumlental space, ciliary muscle contraction is undiminished but
produces diminishing changes zonular tension, and diminishing
changes in lens curvature.
[0180] Embodiments disclosed herein are suitable for combination
with cataract surgery in order to further lower IOP and increase
accommodation, for example. Removing the age-enlarged lens allows
the ciliary muscle to return to a more youthful antero-posterior
location, and provides opening the drainage angle. In accordance
with embodiments, cataract surgery can remove stresses throughout
the uveal tissue by facilitating a reduction in the choroidal
perimeter after the age-enlarged crystalline lens is removed, and
the embodiments disclosed herein are suitable for combination with
cataract surgery.
[0181] The ciliary muscle can remain active throughout life and
lens hardening may not be the cause of presbyopia. Many treatments
as described herein alter the geometry between the ciliary muscle,
zonular apparatus and lens, and can affect the crystalline lens
response to accommodative effort, in order to provide increased
accommodation. The STEM procedure as disclosed herein increases the
circumlental space within a range from about 200 to 800 microns,
for example about 400 microns. MRI studies have demonstrated a
significant age-related decrease in circumlental space
(approximately 470 microns both nasally and temporally over the
adult lifespan), and the increased circumlental space produced by
the STEM procedure as disclosed herein can provide a mechanism for
the improvement in near vision. Changes in the geometric
relationship of the accommodative structures may also lead to a
reduction in IOP when the drainage angle is increased or when
tension of the uvea decreases, for example. Such changes may with
the STEM procedure.
[0182] Examples of suitable studies that can be performed by a
person of ordinary skill in the art in order to determine the
efficacy of the STEM procedure in accordance with embodiments as
disclosed herein are described in the following publications, which
are incorporated by reference in their entirety to the maximum
extent permitted by applicable law and treaties: [0183] Strenk S A,
Semmlow J L, Strenk L M, Munoz P, Gronlund-Jacob J, DeMarco J K.
Age-related changes in human ciliary muscle and lens: a magnetic
resonance imaging study. Invest Ophthalmol Vis Sci 1999;
40:1162-1169. [0184] Strenk S A, Strenk L M, Guo S. Magnetic
resonance imaging of aging, accommodating, phakic, and pseudophakic
ciliary muscle diameters. J Cataract Refract Surg 2006;
32:1792-1798. [0185] Strenk S A, Strenk L M, Semmlow J L. High
resolution MRI study of circumlental space in the aging eye. J
Refract Surg 2000; 16:S659-660. [0186] Strenk S A, Strenk L M,
Koretz J F. The mechanism of presbyopia. Prog Retin Eye Res 2005;
24:379-393. [0187] Strenk S A, Strenk L M, Guo S. Magnetic
resonance imaging of the anteroposterior position and thickness of
the aging, accommodating, phakic, and pseudophakic ciliary muscle.
J Cataract Refract Surg 2010; 36:235-241. [0188] Poley B J,
Lindstrom R L, Samuelson T W. Long-term effects of
phacoemulsification with intraocular lens implantation in
normotensive and ocular hypertensive eyes. J Cataract Refract Surg
2008; 34:735-742. [0189] Poley B J, Lindstrom R L, Samuelson T W,
Schulze Jr R. Intraocular pressure reduction after
phacoemulsification with intraocular lens implantation in
glaucomatous and nonglaucomatous eyes. Evaluation of a causal
relationship between the natural lens and open-angle glaucoma.
Journal of Cataract and Refractive Surgery 2009; 35:1946-1955.
[0190] While preferred embodiments of the present disclosure have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. Numerous variations, changes, and substitutions will
be apparent to those skilled in the art without departing from the
scope of the present disclosure. It should be understood that
various alternatives to the embodiments of the present disclosure
described herein may be employed without departing from the scope
of the present invention. Therefore, the scope of the present
invention shall be defined solely by the scope of the appended
claims and the equivalents thereof.
* * * * *